Site Editor

Jennifer R. Brown, MD, PhD

Advertisement
Advertisement

ASH 2022: Final Analysis of Head-to-Head Comparison of BTK Inhibitors in Resistant CLL

By: Julia Fiederlein Cipriano
Posted: Wednesday, December 14, 2022

Based on a predefined response analysis of the phase III ALPINE trial, zanubrutinib demonstrated a superior overall response rate compared with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The final progression-free survival analysis, which was presented by Jennifer R. Brown, MD, PhD, of the Dana-Farber Cancer Institute, Boston, and colleagues during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract LBA-6), continued to support zanubrutinib as the more efficacious Bruton’s tyrosine kinase (BTK) inhibitor in this setting.

Patients who received at least one prior therapy were randomly assigned in a 1:1 ratio to receive zanubrutinib (n = 327) or ibrutinib (n = 325). In the intention-to-treat population, independent review committee–assessed progression-free survival appeared to be superior with zanubrutinib compared with ibrutinib; investigator-assessed statistical values were found to be identical. The median duration of independent review committee–assessed progression-free survival was 35 months with ibrutinib and not reached with zanubrutinib.

Patients with del(17p)/TP53 mutations experienced longer durations of independent review committee–assessed progression-free survival with zanubrutinib than with ibrutinib. Progression-free survival seemed to consistently favor zanubrutinib across other major predefined subgroups. The independent review committee–assessed overall response (86.2% vs. 75.7%) and partial response with lymphocytosis or better (91.7% vs. 83.1%) rates were higher with zanubrutinib than with ibrutinib.

As for toxicity, patients treated with zanubrutinib experienced lower rates of adverse events of grade 3 or higher (67.3% vs. 70.4%), serious adverse events (42.0% vs. 50.0%), dose interruptions (50.0% vs. 56.8%), and dose reductions (12.3% vs. 17.0%) than those who received ibrutinib. The rates of atrial fibrillation/flutter were 5.2% and 13.3% with zanubrutinib and ibrutinib, respectively; the rates of other adverse events of special interest did not seem to differ between the arms. There were no grade 5 adverse events because of cardiac disorders with zanubrutinib; however, they were reported in 1.9% of patients treated with ibrutinib.

Disclosure: For full disclosures of the study authors, visit ash.confex.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.